Cellular Therapies in Chronic Lymphocytic Leukemia and Richter’s Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant
暂无分享,去创建一个
S. O'brien | C. Coombs | N. Grover | S. Easaw | Catherine C. Coombs | Saumya Easaw | Natalie S. Grover | Susan M. O’Brien | Catherine C Coombs
[1] Analiz Rodriguez,et al. CAR-T Therapies in Solid Tumors: Opportunities and Challenges , 2023, Current Oncology Reports.
[2] A. Moravej,et al. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment , 2022, BMC Cancer.
[3] R. Elstrom,et al. Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies , 2022, Blood.
[4] I. Flinn,et al. ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia , 2022, Blood.
[5] Matthew J. Frigault,et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. , 2022, The Lancet. Haematology.
[6] R. Walgren,et al. Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study. , 2022, Clinical lymphoma, myeloma & leukemia.
[7] Tamara J Laskowski,et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape , 2022, Nature Medicine.
[8] A. Mato,et al. Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare) , 2022, American journal of hematology.
[9] S. Tu,et al. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis. , 2022, Critical reviews in oncology/hematology.
[10] C. Lacan,et al. CAR-NK Cells: A Chimeric Hope or a Promising Therapy? , 2022, Cancers.
[11] S. Slager,et al. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib‐resistant or double‐refractory chronic lymphocytic leukaemia , 2022, British journal of haematology.
[12] M. Grever,et al. Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes , 2022, Blood advances.
[13] P. Riedell,et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. , 2022, The Lancet. Oncology.
[14] A. Moravej,et al. Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review , 2022, Molecular Biology Reports.
[15] R. Houot,et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Kanner,et al. P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY) , 2022, HemaSphere.
[17] I. Flinn,et al. P682: NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF WILD-TYPE AND C481S MUTATED BRUTON TYROSINE KINASE FOR B-CELL MALIGNANCIES: EFFICACY AND SAFETY OF THE PHASE 2 DOSE-EXPANSION BELLWAVE-001 STUDY , 2022, HemaSphere.
[18] D. Maloney,et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial , 2022, The Lancet.
[19] D. Miklos,et al. A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies. , 2022, Journal of Clinical Oncology.
[20] T. Shanafelt,et al. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial , 2022, Blood.
[21] J. Byrd,et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia , 2022, Blood advances.
[22] T. Kipps,et al. Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia , 2022, Cancers.
[23] D. Maloney,et al. High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLL , 2022, Transplantation and Cellular Therapy.
[24] T. Kadia,et al. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors , 2022, Leukemia & lymphoma.
[25] Gregory M. Chen,et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells , 2022, Nature.
[26] O. Oluwole,et al. Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice , 2021, EJHaem.
[27] R. Greil,et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. , 2021, The New England journal of medicine.
[28] M. Kersten,et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. , 2021, The New England journal of medicine.
[29] G. Salles,et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. , 2021, The Lancet. Oncology.
[30] A. Zelenetz,et al. Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax , 2021, Blood.
[31] D. Miklos,et al. ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T , 2021, Blood.
[32] C. Jacobson,et al. Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies , 2021, Blood.
[33] S. de Vos,et al. ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing , 2021, Blood.
[34] M. Juan,et al. The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers , 2021, Cancers.
[35] P. Riedell,et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL , 2021, Blood.
[36] E. Wherry,et al. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. , 2021, Blood.
[37] C. Jacobson,et al. Autologous and Allogeneic Hematopoietic Cell Transplantation for Diffuse Large B-cell Lymphoma-Type Richter Syndrome. , 2021, Blood advances.
[38] E. Thompson,et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition , 2021, Blood advances.
[39] Catherine J. Wu,et al. Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation , 2021, Haematologica.
[40] K. Davis,et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial , 2021, Nature Medicine.
[41] A. Zelenetz,et al. Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. , 2021, Blood advances.
[42] R. Bociek,et al. Outcomes of Richter’s transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database , 2021, Annals of Hematology.
[43] S. Jagannath,et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study , 2021, The Lancet.
[44] R. Houot,et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study , 2021, The Lancet.
[45] J. Chavez,et al. Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions , 2021, International journal of hematologic oncology.
[46] C. Jacobson,et al. Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL. , 2021 .
[47] P. Riedell,et al. Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study. , 2021 .
[48] P. Shou,et al. CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells , 2021, Clinical Cancer Research.
[49] Michael L. Wang,et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study , 2021, The Lancet.
[50] H. Goldschmidt,et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.
[51] P. Dreger. Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia? , 2021, Cancer journal.
[52] Matthew J. Frigault,et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies , 2020, The Lancet.
[53] K. Dorritie,et al. Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) , 2020 .
[54] Paul C. Rogers,et al. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy , 2020, Science Translational Medicine.
[55] Jiang F Zhong,et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant , 2020, Leukemia.
[56] S. Rosenberg,et al. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] P. Hari,et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial , 2020, Nature Medicine.
[58] J. Byrd,et al. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. , 2020, Blood advances.
[59] Catherine J. Wu,et al. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. , 2020, Blood advances.
[60] Michael L. Wang,et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.
[61] A. Zelenetz,et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. , 2020, Blood advances.
[62] S. Galimberti,et al. Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities. , 2020, The Journal of clinical investigation.
[63] R. Fanin,et al. Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[64] Zhiqiang Wu,et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. , 2020, Blood.
[65] Yucai Wang,et al. Richter transformation of chronic lymphocytic leukemia in the era of novel agents. , 2020, Clinical advances in hematology & oncology : H&O.
[66] D. Porter,et al. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] A. Roberts,et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. , 2020, Blood.
[68] A. Zelenetz,et al. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy , 2020, Clinical Cancer Research.
[69] D. Maloney,et al. Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure. , 2020, Blood.
[70] P. Thall,et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.
[71] A. Chanan-Khan,et al. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis , 2019, Hematology/oncology and stem cell therapy.
[72] R. Varadhan,et al. Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplant Cyclophosphamide in Chronic Lymphocytic Leukemia. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[73] G. Inghirami,et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies , 2019, Science Translational Medicine.
[74] A. Ho,et al. Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis , 2019, Haematologica.
[75] M. Lunning,et al. SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B‐CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY , 2019, Hematological Oncology.
[76] J. Byrd,et al. ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). , 2019, Journal of Clinical Oncology.
[77] Yu-Hong Chen,et al. Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal Residual Disease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation , 2019, Engineering.
[78] G. Sobol-Milejska,et al. NK Cells as Possible Prognostic Factor in Childhood Acute Lymphoblastic Leukemia , 2019, Disease markers.
[79] G. Salles,et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.
[80] D. Miklos,et al. End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma , 2018, Biology of Blood and Marrow Transplantation.
[81] M. Sadelain,et al. A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation , 2018, Blood.
[82] M. Stetler-Stevenson,et al. Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22 , 2018, Molecular therapy oncolytics.
[83] Matthew J. Frigault,et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. , 2018, Blood.
[84] J. Orange,et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity , 2018, Leukemia.
[85] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[86] Jeffrey A Jones,et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. , 2018, The Lancet. Oncology.
[87] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[88] J. Byrd,et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] Jeffrey A Jones,et al. Ibrutinib treatment improves T cell number and function in CLL patients , 2017, The Journal of clinical investigation.
[90] H. Putter,et al. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation , 2017, Bone Marrow Transplantation.
[91] A. Hackshaw,et al. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia , 2017, Leukemia.
[92] C. June,et al. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms , 2017, Leukemia.
[93] Christopher M. DeBoever,et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. , 2016, Blood.
[94] S. Grupp,et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. , 2016, The Journal of clinical investigation.
[95] C. Wendtner,et al. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells. , 2016, Blood.
[96] S. Rosenberg,et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] Hao Liu,et al. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. , 2016, The Journal of clinical investigation.
[98] S. Grupp,et al. Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL. , 2016 .
[99] J. Byrd,et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. , 2016, Blood.
[100] M. Sadelain,et al. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. , 2015, Cancer cell.
[101] David L. Porter,et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.
[102] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] C. Cruz,et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.
[104] S. Riddell,et al. Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells , 2013, Clinical Cancer Research.
[105] J. Gribben,et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. , 2013, Blood.
[106] J. Gribben,et al. Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome , 2012, Leukemia.
[107] B. Djulbegovic,et al. Successful allogeneic cord blood transplantation in a patient with Evans syndrome leads to correction of hereditary angioedema type I as secondary effect , 2012, Bone Marrow Transplantation.
[108] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[109] S. Pileri,et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. , 2011, Blood.
[110] J. Briones,et al. Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[111] A. Prentice,et al. Abnormal T-cell Function in B-cell Chronic Lymphocytic Leukaemia , 2003, Leukemia & lymphoma.